Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection shows promise for tough kidney cancer

NCT ID NCT04169711

Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had gotten worse after other treatments. The main goal was to find a safe dose and check for side effects. This is an early-phase trial, so it focuses on safety and dosing, not yet on curing the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

26 people

The number who actually took part.

Started

Aug 2020

Finished

Jul 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception * Willing to provide written informed consent and to comply with study requirements * Histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma that has progressed during or after at least two prior therapeutic regimens which must include vascular endothelial growth factor (VEGF)-targeted therapy and checkpoint inhibitor therapy or that has otherwise failed such therapies, is measurable disease per RECIST 1.1 criteria, is biopsy accessible * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Estimated life expectancy of longer than 3 months * Adequate organ function at screening Exclusion Criteria: * History of untreated brain metastasis or leptomeningeal disease or spinal cord compression * Failure to recover from reversible effects of prior anti-cancer therapy * Has received systemic therapy or radiation therapy within 2 weeks prior to first dose * History of solid organ or stem cell transplantation * Current use of anti-VEGF or mammalian target of rapamycin (mTOR) agents, or chronic immunosuppressive therapy * Any prior use of hypoxia inducible factor 2 (HIF2) inhibitors within 6 months prior to first dose * Current use of immune checkpoint inhibitors * Use of an investigational agent or device within 2 weeks prior to dosing, or current participation in an investigational study * Known HIV, hepatitis B or hepatitis C * History of other clinically meaningful disease * Major surgery within 4 weeks of Screening * Active malignancy requiring therapy other than ccRCC within 3 years of study entry Note: Other eligibility criteria may apply per protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced clear cell renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clear cell renal cell carcinoma

Contacts and locations

Locations

  • Research Site 1

    Aurora, Colorado, 80045, United States

  • Research Site 2

    Las Vegas, Nevada, 89169, United States

  • Research Site 4

    Nashville, Tennessee, 37232, United States

  • Research Site 5

    Dallas, Texas, 75390, United States

  • Research Site 6

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.